A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
High-grade Serous Ovarian Carcinoma (HGSOC)|Uterine Serous Carcinoma (USC)|Non-small Cell Lung Cancer (NSCLC)
DRUG: BMS-986463
Number of participants with adverse events (AEs), Up to 108 weeks|Number of participants with serious adverse events (SAEs), Up to 108 weeks|Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria, Up to 108 weeks|Number of participants with AEs leading to discontinuation, Up to 108 weeks|Number of participants with AEs leading to death, Up to 108 weeks
Maximum observed concentration (Cmax), Up to 104 weeks|Area under the concentration-time curve (AUC), Up to 104 weeks|Time of maximum observed concentration (Tmax), Up to 104 weeks|Objective response rate (ORR), Up to 104 weeks|Disease control rate (DCR), Up to 104 weeks|Duration of response (DOR), Up to 104 weeks
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.